# A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

> **NCT05557045** · PHASE1 · RECRUITING · sponsor: **Jazz Pharmaceuticals** · enrollment: 332 (estimated)

## Conditions studied

- Advanced Cancer
- Metastatic Cancer
- Solid Tumor

## Interventions

- **DRUG:** JZP815

## Key facts

- **NCT ID:** NCT05557045
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-10
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 332 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05557045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05557045, "A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05557045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*